Efficacy and safety of bivalirudin application during primary percutaneous coronary intervention in older patients with acute ST-segment elevation myocardial infarction

Hongwu Chen¹,*, Xiaofan Yu¹,²,*, Xiangyong Kong¹, Longwei Li¹, Jiawei Wu¹ and Likun Ma¹

Abstract

Objective: ST-segment elevation myocardial infarction (STEMI) is the most serious type of acute coronary syndrome. This study aimed to investigate the efficacy and safety of bivalirudin application during primary percutaneous coronary intervention (PPCI) in older patients with acute STEMI.

Methods: A total of 672 older patients with STEMI (>75 years) who underwent PPCI were studied. The primary endpoints were 30-day net adverse clinical events (NACEs) post-emergency percutaneous coronary intervention, including major adverse cardiac and cerebrovascular events (MACCEs) and Bleeding Academic Research Consortium grades 2 to 5 (BARC 2–5) bleeding events.

Results: The incidence of NACEs and BARC 2–5 bleeding events in the bivalirudin group was significantly lower than that in the unfractionated heparin group. Multivariate Cox regression analysis showed that bivalirudin significantly reduced 30-day NACEs (odds ratio: 0.700, 95% confidence interval: 0.492–0.995) and BARC 2–5 bleeding events (odds ratio: 0.561, 95% confidence interval: 0.379–0.835).

*Hongwu Chen and Xiaofan Yu contributed equally to this work.

Corresponding author:
Likun Ma, Department of Cardiology, The First Affiliated Hospital of USTC (Anhui Provincial Hospital), Division of Life Sciences and Medicine, University of Science and Technology of China, No. 17 Lujiang Road, Luyang District, Hefei, Anhui Province 230001, China.
Email: lkmai19@163.com
confidence interval: 0.343–0.918). At 1-year follow-up, these results were similar. **Conclusions:** Bivalirudin can be safely and effectively used during PPCI in older patients with STEMI. Bivalirudin reduces the risks of NACEs and bleeding within 30 days after PPCI, without increasing the risks of MACCEs and stent thrombosis compared with heparin.

**Keywords**
Bivalirudin, unfractionated heparin, ST-segment elevation myocardial infarction, primary percutaneous coronary intervention, older patient, major adverse cardiac and cerebrovascular events

Date received: 9 March 2020; accepted: 16 July 2020

**Introduction**
Coronary artery disease refers to plaques or stenosis of the coronary artery, limited or diffuse spasm of the coronary artery, small-vessel disease, and microvascular dysfunction, and it is the main cause of death worldwide.\(^1,2\) ST-segment elevation myocardial infarction (STEMI) occurs on the basis of coronary artery disease with a sharp reduction or interruption of coronary blood supply, resulting in myocardial infarction caused by severe and persistent myocardial ischemia. With an aging society in China, the incidence of STEMI is rising in the older population.

Primary percutaneous coronary intervention (PPCI) is still the preferred reperfusion method in older patients with STEMI.\(^3\) PPCI therapy can rescue blocked blood vessels in time, restore myocardial blood perfusion, and significantly reduce the mortality and recurrence rates of infarction.\(^4\) Current guidelines recommend routine anticoagulation during PPCI in patients with STEMI.\(^5\) In addition to the treatment strategy and standard operation, the efficacy and safety of anticoagulant drugs in PPCI are important for a successful operation. In particular, older patients with STEMI have more risk factors of cardiovascular events than younger patients. Therefore, the risks of ischemia and bleeding during percutaneous coronary intervention (PCI) are higher in older patients.\(^6,7\) Consequently, the benefits and risks of intra-PCI anticoagulation must be weighed in older patients.

Unfractionated heparin (UFH) has been used for decades in patients with STEMI undergoing PPCI.\(^8\) In addition to UFH, the use of aspirin, clopidogrel, and glycoprotein IIb/IIIa inhibitors (GPIs) has been shown to reduce early and late adverse cardiac events in patients with STEMI, with an unnecessary increase in bleeding events.\(^9,10\) Bivalirudin is a novel direct thrombin inhibitor. Several large multicenter trials (EuroMAX,\(^11\) HORISON AMI\(^12\)) showed that during PPCI in patients with STEMI, bivalirudin was superior to UFH alone or in combination with a GPI in reducing bleeding events. However, the efficacy and safety of bivalirudin has not been established in older patients. Therefore, this study was designed to investigate the perioperative efficacy and safety of bivalirudin during emergency PPCI in older patients (>75 years old) with STEMI.

**Patients and methods**

**Patients**
Patients with STEMI who underwent PPCI in our hospital between February 2011 and December 2019 were included in this study. Inclusion criteria were as follows: (1) age ≥75 years (men and women); (2) a primary PPCI strategy was followed for patients with symptoms lasting longer than 12 hours in the presence of (i) evidence of a
persistent ischemic electrocardiogram (ECG); (ii) persistent or recurrent pain and dynamic ECG changes; and (iii) persistent or recurrent pain, symptoms, and signs of heart failure, shock, or malignant arrhythmias; (3) no revascularization for other non-culprit target vessels within 30 days after PPCI; and (4) use of antiplatelet agents (aspirin and clopidogrel or ticagrelor, and a loading or maintenance dose) before PCI according to relevant guidelines.

Exclusion criteria were as follows: (1) intravenous thrombolytic therapy; (2) use of anticoagulants (heparin/low molecular weight heparin, sodium fondaparinux, warfarin, or new oral anticoagulants) or tirofiban within 48 hours before PCI; (3) intraoperative or postoperative intravenous infusion of a GPI; and (4) mechanical complications, such as ventricular septal rupture, papillary muscle rupture, and acute mitral regurgitation. This study was approved by the ethics committee of Anhui Provincial Hospital and all patients signed written informed consent.

Clinical data collection

For eligible participants, the baseline characteristics (sex, age, coronary risk factors, and laboratory tests), clinical medications, and detailed PPCI data were collected by designated staff involved in the study. The preoperative estimated glomerular filtration rate (eGFR) was calculated using the modified diet in renal disease study equation applicable for the Chinese population of adult men: \[ \text{eGFR (mL/minute/1.73 m}^2\) = 175 \times (\text{serum creatinine}^{-1.234} \times (\text{age}^{-0.179}) \times (\text{women} \times 0.79). \] Patients were followed up by phone or clinical follow-up for 30 days after the emergency PCI. The primary clinical endpoint was net adverse clinical events (NACEs) 30 days after emergency PCI, including major adverse cardiac and cerebral events (MACCEs) and Bleeding Academic Research Consortium grades 2 to 5 (BARC 2–5) bleeding events. \[ \] MACCEs included all-cause death, recurrent myocardial infarction, ischemia-driven target vessel revascularization, and stroke. Secondary endpoints were MACCEs 30 days after emergency PCI, BARC 2–5 bleeding events 30 days after surgery, and stent thrombosis. Stent thrombosis was defined according to the Academic Research Consortium (ARC) (defined as certain or probable stent thrombosis).

Medical treatment and main considerations of PCI

According to the anticoagulants provided during PPCI, patients with STEMI were divided into the bivalirudin group and the UFH group (n = 260). Patients in both groups took a single dose of aspirin (100–300 mg) and clopidogrel (300–600 mg) or ticagrelor (180 mg) before PPCI. In the bivalirudin group, bivalirudin (250 mg/vial; Salubris Pharmaceutical Co., Ltd., Shenzhen, China) was administered at a dose of 0.75 mg/kg (intravenously) during PPCI, followed by a maintenance dose of 1.75 mg/kg/hour intravenously. The activated clotting time (ACT) was monitored 5 minutes after initial administration. If the ACT was <225 s (Hemotec methods), additional bivalirudin (0.30 mg/kg, injection) was provided. At 30 minutes after the end of PCI, the interventional cardiologist decided whether to administer bivalirudin (1.75 mg/kg, intravenously) as required for no longer than 4 hours (starting from this dose). Patients in the UFH group were provided a loading dose (100 U/kg) of UFH. The ACT was monitored for 5 minutes after initial administration. If the ACT exceeded 225 s, an UFH (20 U/kg) bolus was administered.

Coronary angiography was performed via radial, femoral, or brachial access. Single-vessel or multi-vessel lesions were considered on the basis of the number of
coronary lesions with \( \geq 50\% \) stenosis. PPCI was performed after recording the type of lesion and the extent of calcification. For patients with left ventricular dysfunction or cardiogenic shock, an intra-aortic balloon pump was placed before PPCI. For patients with severe bradycardia, a temporary pacemaker was implanted before PPCI. After PPCI, the patients were instructed to take aspirin (100 mg, once daily) and clopidogrel (75 mg, once daily) or ticagrelor (90 mg, twice a day). After PPCI, the physician made a decision regarding the use of low molecular weight heparin on the basis of the patient’s condition.

**Definitions**

Anemia was defined as hemoglobin levels < 120 g/L for adult men or hemoglobin levels < 110 g/L for adult women. All-cause death was defined as death associated with any cause. Cardiac death was defined as any death associated with cardiac factors (e.g., myocardial infarction, low-output heart failure, and fatal arrhythmia), undocumented death, unexplained death, and all procedure-related deaths, including concurrent treatment-related deaths. Myocardial infarction was defined according to the third edition of the updated global definition of myocardial infarction, which was released at the European Society of Cardiology conference in 2012 as typical chest pain for \( \geq 30 \) minutes, with evolving ECG changes and creatine kinase and creatine kinase isoenzyme MB levels \( > 3 \times \) the upper limit of normal or troponin T levels \( > 1 \times \) the upper limit of normal. Ischemia-driven target vessel revascularization was defined as second PCI or coronary artery bypass grafting (CABG) due to re-stenosis of the target lesion or any part of the same major vessel (proximal part, distal part, branches, and the left main trunk) or to other reasons. Stroke was defined as an acute non-hemorrhagic cerebrovascular event that caused local or global neurological dysfunction, with symptoms lasting longer than 24 hours, and confirmation by clinical symptoms and imaging studies.

**Statistical analysis**

Categorical variables are expressed as percentage and were analyzed with the chi-square test or Fisher’s exact test. Continuous variables are expressed as mean ± standard deviation and were analyzed with the t-test or analysis of variance. Multivariate logistic regression was used to examine the effect of patients’ characteristics on the selection of a “one-time” procedure or staged approach. We adjusted all available variables listed in Table 1. The Kaplan–Meier method was used to analyze adverse events that occurred during follow-up. The Cox proportional hazard regression model was used to analyze the association between bivalirudin and the study endpoints during follow-up. Variables associated with primary endpoints (\( P < 0.1 \)) as per univariate analysis and clinically relevant variables, including age, sex, anemia, diabetes, hypertension, stroke history, eGFR \( \leq 60 \) mL/minute/1.73 m\(^2\), and intervention access, were incorporated into the regression model. SPSS v24.0 (IBM Corp. Armonk, NY, USA) was used for statistical analysis. All tests were two-sided and \( P < 0.05 \) was considered to be statistically significant.

**Results**

**Clinical characteristics**

A total of 672 patients with STEMI were included, and there were 412 patients in the bivalirudin group and 260 in the UFH group. The basic clinical characteristics of patients with STEMI are shown in Table 1. Patients in the bivalirudin group were significantly older than those in the UFH group (\( P < 0.001 \)) and the incidence of
anemia (P = 0.015) was significantly higher than that in the UFH group. Additionally, the femoral artery was more frequent for arterial access in the bivalirudin group than in the UFH group (P = 0.043). The hospital stay in the bivalirudin group was significantly shorter than that in the UFH group (P = 0.005) (Table 2).

**NACEs 30 days after PPCI**

During the 30-day follow-up after PPCI, the rate of NACEs tended to be lower in the bivalirudin group than in the UFH group (P = 0.053) (Table 3). Multivariate Cox regression analysis showed that the incidence of NACEs was significantly lower in the bivalirudin group than in the UFH group (P = 0.047) (Table 3). The multivariate logistic regression model showed that patients with arterial access (femoral artery) (P = 0.033) and older age (P < 0.001) were more likely to use bivalirudin (Table 4).

**MACCEs 30 days after PPCI**

During the 30-day follow-up after PPCI, there was no significant difference in the incidence of MACCEs between the two groups (Table 3). Multivariate Cox regression analysis also showed that there was no significant difference in the incidence of MACCEs between the two groups. Moreover, for MACCEs, no significant difference was observed in all-cause mortality, cardiac death, recurrent myocardial infarction, stroke, or target vessel revascularization between the two groups (Table 3).

**BARC 2–5 bleeding events 30 days after PPCI**

During the 30-day follow-up after PPCI, the rate of BARC 2–5 bleeding events was significantly lower in the bivalirudin group than in the UFH group (P = 0.035). Moreover, multivariate Cox regression analysis showed that the incidence of BARC 2–5 bleeding events was significantly lower in the bivalirudin group than in the UFH group.

### Table 1. Basic clinical characteristics.

| Variable                          | Bivalirudin group (n = 412)       | UFH group (n = 260)         | P value |
|-----------------------------------|----------------------------------|----------------------------|---------|
| Age (years)                       | 80.34 ± 4.54                    | 78.73 ± 3.92               | <0.001  |
| Men, n (%)                        | 257 (62.4)                      | 157 (60.4)                 | 0.605   |
| Heart rate, beats/minute          | 77.40 ± 19.48                   | 78.28 ± 19.74              | 0.566   |
| LVEF, %                           | 52.09 ± 11.88                   | 52.11 ± 12.14              | 0.984   |
| History of hypertension, n (%)    | 239 (58.0)                      | 152 (58.5)                 | 0.908   |
| History of stroke, n (%)          | 86 (20.9)                       | 41 (15.8)                  | 0.100   |
| History of MI, n (%)              | 32 (7.8)                        | 27 (10.4)                  | 0.243   |
| History of diabetes, n (%)        | 115 (27.9)                      | 77 (29.6)                  | 0.634   |
| eGFR ≤60 mL/minute/1.73 m², n (%) | 122 (29.6)                      | 75 (28.8)                  | 0.832   |
| Anemia, n (%)                     | 124 (30.1)                      | 56 (21.5)                  | 0.015   |
| Killip grade, n (%)               |                                 |                            | 0.912   |

Continuous variables are expressed as mean ± standard deviation and categorical variables are expressed as n (%). UFH, unfractionated heparin; LVEF, left ventricular ejection fraction; MI, myocardial infarction; eGFR, estimated glomerular filtration rate.
### Table 2. Treatment and procedural characteristics.

| Variable                      | Bivalirudin group (n = 412) | UFH group (n = 260) | P value |
|-------------------------------|----------------------------|---------------------|---------|
| IRA, n (%)                   |                            |                     | 0.992   |
| Left main artery             | 10 (2.4)                   | 7 (2.7)             |         |
| Left anterior descending artery | 203 (49.3)                | 130 (50.0)          |         |
| Left circumflex artery       | 53 (12.9)                  | 33 (12.7)           |         |
| Right artery                 | 146 (35.4)                 | 90 (34.6)           |         |
| Lesion number, n (%)         |                            |                     | 0.500   |
| 1                             | 111 (26.9)                 | 81 (31.2)           |         |
| 2                             | 139 (33.7)                 | 83 (31.9)           |         |
| 3                             | 162 (39.3)                 | 96 (36.9)           |         |
| Left main trunk, n (%)       |                            |                     | 0.917   |
| IABP, n (%)                  | 44 (10.7)                  | 28 (10.8)           |         |
| Arterial access, n (%)       |                            |                     | 0.678   |
| Radial artery                | 347 (84.2)                 | 234 (90.0)          |         |
| Brachial artery              | 37 (9.0)                   | 19 (7.3)            |         |
| Femoral artery               | 28 (6.8)                   | 7 (2.7)             |         |
| Stent number                 | 1.40 ± 0.73                | 1.38 ± 0.71         | 0.828   |
| Total stent length, mm       | 35.99 ± 20.89              | 36.34 ± 26.18       | 0.878   |
| Hospital stay, days          | 7 (6–10)                   | 8 (6–12)            | 0.005   |

Normally distributed continuous variables are expressed as mean ± standard deviation and categorical variables are expressed as n (%). UFH, unfractionated heparin; IRA, infarction-related artery; IABP, intra-aortic balloon pump.

### Table 3. Thirty-day adverse events after emergency percutaneous coronary intervention in older patients with ST-segment elevation myocardial infarction.

| Clinical event, n (%) | Bivalirudin group (n = 412) | UFH group (n = 260) | Crude | Adjusted |
|-----------------------|----------------------------|---------------------|-------|----------|
|                       | OR (95% CI)                | P value             | OR (95% CI) | P value  |
| NACEs                 | 0.731 (0.518–1.030)        | 0.053               | 0.700 (0.492–0.995) | 0.047 |
| MACCEs                | 0.832 (0.533–1.299)        | 0.416               | 0.778 (0.456–1.329) | 0.358 |
| All-cause death       | 0.901 (0.556–1.461)        | 0.673               | 0.812 (0.487–1.353) | 0.424 |
| Cardiac death         | 0.841 (0.511–1.386)        | 0.496               | 0.861 (0.526–1.410) | 0.551 |
| MI                    | 0.950 (0.159–5.686)        | 0.955               | 1.014 (0.162–6.357) | 0.988 |
| Stroke                | 0.628 (0.039–10.033)       | 0.742               | 0.781 (0.203–3.005) | 0.719 |
| TVR                   | 0.506 (0.136–1.883)        | 0.309               | 0.848 (0.047–15.187) | 0.911 |
| BARC 2–5              | 0.602 (0.373–0.972)        | 0.035               | 0.561 (0.343–0.918) | 0.021 |
| BARC 2                | 0.661 (0.353–1.238)        | 0.191               | 0.660 (0.346–1.259) | 0.207 |
| BARC 3–5              | 0.542 (0.258–1.139)        | 0.100               | 0.479 (0.223–1.029) | 0.059 |
| Stent thrombosis       | 0.950 (0.159–5.686)        | 0.955               | 1.014 (0.162–6.357) | 0.988 |
| Certain               | 0.631 (0.039–10.091)       | 0.745               | 1.357 (0.069–26.726) | 0.841 |
| Probable              | 1.270 (0.115–14.003)       | 0.845               | 1.252 (0.104–15.010) | 0.859 |

UFH, unfractionated heparin; OR, odds ratio; CI, confidence interval; NACEs, net adverse clinical events; MACCEs, major adverse cardiac and cerebrovascular events; BARC, Bleeding Academic Research Consortium.
**Table 4.** Multivariate logistic regression model of arterial access (femoral artery) or older age for use of bivalirudin.

| Variables                                      | HR (95% CI)          | P value |
|------------------------------------------------|----------------------|---------|
| Arterial access (femoral artery vs radial artery) | 2.584 (1.078–6.192) | 0.033   |
| Age                                            | 1.096 (1.051–1.143)  | <0.001  |

HR, hazard ratio; CI, confidence interval.

**Table 5.** One-year adverse events after emergency percutaneous coronary intervention in older patients with ST-segment elevation myocardial infarction.

| Clinical event, n (%) | Bivalirudin group | UFH group | Crude OR (95% CI) | Adjusted OR (95% CI) |
|-----------------------|------------------|-----------|-------------------|----------------------|
| NACEs                 | 108(26.3)        | 71(27.6)  | 0.926 (0.687–1.250) | 0.644 0.878 (0.647–1.192) | 0.404 |
| MACCEs                | 80 (19.6)        | 48 (18.9) | 1.025 (0.717–1.466) | 0.892 0.951 (0.660–1.371) | 0.789 |
| All-cause death       | 73 (17.8)        | 40 (15.4) | 1.138 (0.774–1.673) | 0.510 1.025 (0.692–1.518) | 0.902 |
| Cardiac death         | 67 (16.4)        | 38 (14.8)| 1.099 (0.738–1.637) | 0.640 1.005 (0.669–1.508) | 0.982 |
| MI                    | 10 (2.7)         | 6 (2.7)   | 1.036 (0.377–2.850) | 0.945 1.072 (0.379–3.030) | 0.896 |
| Stroke                | 2 (0.8)          | 2 (0.5)   | 0.613 (0.086–4.356) | 0.622 0.711 (0.084–5.994) | 0.754 |
| TVR                   | 5 (1.3)          | 6 (2.5)   | 0.528 (0.161–1.729) | 0.283 0.819 (0.245–2.736) | 0.745 |
| BARC 2–5              | 40 (9.8)         | 31 (12.1)| 0.799 (0.500–1.278) | 0.346 0.792 (0.489–1.281) | 0.342 |
| BARC 2                | 29 (7.5)         | 20 (8.0)  | 0.904 (0.511–1.597) | 0.727 0.912 (0.508–1.640) | 0.759 |
| BARC 3–5              | 18 (4.7)         | 18 (7.2)  | 0.632 (0.329–1.214) | 0.164 0.552 (0.282–1.083) | 0.084 |
| Stent thrombosis      | 3 (0.8)          | 3 (1.3)   | 0.628 (0.127–3.114) | 0.566 0.668 (0.129–3.477) | 0.632 |
| Certain               | 1 (0.3)          | 2 (0.9)   | 0.311 (0.028–3.433) | 0.314 0.327 (0.026–4.075) | 0.385 |
| Probable              | 2 (0.5)          | 1 (0.4)   | 1.268 (0.115–13.987) | 0.846 1.246 (0.104–14.935) | 0.862 |

UFH, unfractionated heparin; OR, odds ratio; CI, confidence interval; NACEs, net adverse clinical events; MACCEs, major adverse cardiac and cerebrovascular events; MI, myocardial infarction; TVR, target vessel revascularization; BARC, Bleeding Academic Research Consortium.

(P = 0.021). BARC 2 and BARC 3–5 bleeding events were not significantly different between the two groups (Table 3).

**Stent thrombosis and adverse events 30 days after PCI**

During the 30-day follow-up after PCI the rate of stent thrombosis was not significantly different between the two groups (Table 3). The 1-year composite rate of NACEs was not significantly different between the two groups (Table 5). The 1-year incidence of MACCEs was also not significantly different between the two groups. Additionally, there were no significant differences in the 1-year rates of BARC 2–5 bleeding events, cardiac death, myocardial infarction, definite/probable stent thrombosis, and target vessel revascularization between the two groups.

**Discussion**

In recent years, the recommended class for the use of bivalirudin in patients with STEMI during PCI has been evolving. According to the HORIZONS-AMI, EUROMAX, HEAT-PPCI, and BRIGHT studies, the 2014 European Society of Cardiology Revascularization Guidelines and the 2017 European
Society of Cardiology STEMI Guidelines recommended bivalirudin as a class IIa perioperative anticoagulant for patients with STEMI. However, according to additional evidence from the MATRIX and SWEDEHEART studies, the 2018 European Society of Cardiology Revascularization Guidelines recommended bivalirudin as a class IIb anticoagulant. Therefore, the use of bivalirudin during emergency PPCI requires more evidence, and no such studies have been conducted, specifically in older patients with STEMI. The current study showed that in older patients with STEMI, bivalirudin significantly reduced the incidence of NACEs in 30 days after emergency PPCI compared with UFH. This was achieved mainly owing to fewer bleeding events, without increasing the incidence of MACCEs, all-cause death, cardiac death, stroke, recurrent myocardial infarction, target vessel revascularization, and stent thrombosis.

Studies have shown that age is an independent risk factor for bleeding, and the risk of bleeding increases by 2% for each additional year of age. Bleeding events are independent predictors of death after PPCI, and therefore, reducing bleeding events can improve short-term and long-term outcomes. Therefore, for older patients with STEMI at a high risk for bleeding, choosing an anticoagulant during PPCI to reduce the risk of bleeding is important. Compared with traditional UFH, bivalirudin has a shorter half-life, higher bioavailability, and more stable anticoagulant effect. Large studies, such as HORIZONS-AMI and EUROMAX, showed that bivalirudin significantly reduced the incidence of bleeding complications in patients with STEMI who underwent PPCI compared with UFH. The BRIGHT study showed that the effect of bivalirudin lasted 2 to 4 hours after PPCI compared with UFH, which significantly reduced the risk of bleeding without increasing the risk of stent thrombosis. The MATRIX study showed that bivalirudin reduced all-cause death and cardiac death, while reducing the risk of bleeding, compared with UFH alone. The above-mentioned evidence suggests that bivalirudin has more pronounced clinical benefits than UFH for older patients at a high risk of bleeding.

The REPLACE 2 study showed that for older patients aged 75 years and older, bivalirudin reduced 1-year mortality compared with UFH plus a GPI. In the ACUITY study, subgroup analysis showed that bivalirudin reduced major and minor bleeding events in all age groups, especially in patients aged 75 years and older. Additionally, the overall analysis and subgroup analysis per age group showed that bivalirudin did not increase the incidence of ischemic events and death. Lemesle et al. were one of the first research groups to evaluate the perioperative efficacy and safety of bivalirudin in patients aged 80 years and older undergoing PCI. These authors found that bivalirudin reduced the incidence of in-patient bleeding events and post-PCI 6-month mortality compared with UFH. In an age-based subgroup analysis of the combined HORIZONS-AMI and EUROMAX datasets, bivalirudin was associated with a lower 30-day incidence of non-coronary artery bypass grafting major bleeding and NACEs, with a similar 30-day incidence of acute stent thrombosis and mortality in patients aged 65 years and older with acute STEMI. The studies described above enrolled any patient with coronary heart disease who underwent selective PPCI or PPCI. However, our study enrolled older patients with STEMI who underwent PPCI, and we found that bivalirudin consistently showed clinical benefits across the older population. In a previous study, the adjusted risks for 1-year mortality, and 30-day and 1-year
stent thrombosis and re-infarction were not significantly different between patients with STEMI and UFH + GPI and those with bivalirudin + GPI. In this study, we analyzed the efficacy and safety of bivalirudin alone and UFH alone.

This study has some limitations. First, this was a single-center retrospective study, with certain selection bias and confounding factors. Randomized, controlled trials are required to validate the results. Second, during follow-up, ECG, myocardial markers, and imaging studies were not performed or tested in the case of angina, which may have contributed to underestimation of the incidence of myocardial infarction.

Bivalirudin can be safely and effectively used during emergency PPCI in older patients with STEMI. Bivalirudin significantly reduces 30-day NACEs and bleeding events without increasing the risk of MACCEs or stent thrombosis compared with UFH.

Author contributions
Hongwu Chen is responsible for the experimental design, data and statistical analysis, and preparing the manuscript; Xiaofan Yu is responsible for the concept of the study, literature research, and acquisition of data; Xiangyong Kong, Longwei Li, and Jiawei Wu are responsible for the concept of the study and acquisition of data; and Likun Ma is the guarantor of integrity of the entire study, and provided the concept of the study, designed the study, performed clinical treatment, and performed acquisition of data. All authors approved the final version.

Declaration of conflicting interest
The authors declare that there is no conflict of interest.

Funding
The project was supported by the Science Project of Anhui Provincial Cardiovascular Institute (KF2018007), the Scientific and Technological Project of Anhui Province (1604a0802074), and the “Borrow to transfer to supplement” Project of Hefei Independent Innovation Policy (Grant No. J2019Y02).

ORCID iD
Likun Ma https://orcid.org/0000-0003-3993-847X

References
1. Okrainec K, Banerjee DK and Eisenberg MJ. Coronary artery disease in the developing world. Am Heart J 2004; 148: 7–15.
2. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095–2128.
3. Bueno H, Betriu A, Heras M, et al. Primary angioplasty vs. fibrinolysis in very elderly patients with acute myocardial infarction: TRIANA (TRatamiento del Infarto Agudo de miocardio eN Ancianos) randomized trial and pooled analysis with previous studies. Eur Heart J 2011; 32: 51–60.
4. Cui K, Lyu S, Song X, et al. Long-term safety and efficacy of staged percutaneous coronary intervention for patients with ST-segment elevation myocardial infarction and multivessel coronary disease. Am J Cardiol 2019; 124: 334–342.
5. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation myocardial infarction and multivessel coronary disease. Am J Cardiol 2017; 124: 334–342.
6. Fox KA, Dabbous OH, Gelderlyberg RJ, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ 2006; 333: 1091.
7. Moscucci M, Fox KA, Cannon CP, et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003; 24: 1815–1823.
8. Qaderdan K, Vos GA, McAndrew T, et al. Outcomes in elderly and young patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin versus heparin: Pooled analysis from the EUROMAX and HORIZONS-AMI trials. *Am Heart J* 2017; 194: 73–82.

9. Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-R: OASIS 7): a randomised factorial trial. *Lancet* 2010; 376: 1233–1243.

10. Lin GM and Han CL. Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials. *Eur Heart J* 2010; 31: 753–754.

11. Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. *J Am Soc Nephrol* 2006; 17: 2937–2944.

12. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. *Circulation* 2011; 123: 2736–2747.

13. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. *Circulation* 2007; 115: 2344–2351.

14. Steg PG, Van’t Hof A, Hamm CW, et al. Bivalirudin started during emergency transport for primary PCI. *N Engl J Med* 2013; 369: 2207–2217.

15. Shahzad A, Kemp I, Mars C, et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. *Lancet* 2014; 384: 1849–1858.

16. Han Y, Guo J, Zheng Y, et al. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction. *JAMA* 2015; 313: 1336–1346.

17. Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur J Cardiothorac Surg* 2014; 46: 517–592.

18. Valgimigli M, Frigoli E, Leonardi S, et al. Bivalirudin or unfractionated heparin in acute coronary syndromes. *N Engl J Med* 2015; 373: 997–1009.

19. Erlinge D, Omerovic E, Frobert O, et al. Bivalirudin versus heparin monotherapy in myocardial infarction. *N Engl J Med* 2017; 377: 1132–1142.

20. Neumann FJ, Sousa-Uva M and Ahlsson A. 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J* 2018; 39: 3759.

21. Genereux P, Giustino G, Witzenbichler B, et al. Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention. *J Am Coll Cardiol* 2015; 66: 1036–1045.

22. Chen Y, Dong W, Wan Z, et al. Ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome: a pharmacodynamic analysis. *Int J Cardiol* 2015; 201: 545–546.

23. Pellaton C, Cayla G, Silvain J, et al. Incidence and consequence of major bleeding in primary percutaneous intervention for ST-elevation myocardial infarction in the era of radial access: an analysis of the international randomized Acute myocardial infarction Treated with primary angioplasty and intravenous enoxaparin Or UFH to Lower ischemic and bleeding events at short- and Long-term follow-up trial. *Am Heart J* 2015; 170: 778–786.

24. Yoon YH, Kim YH, Kim SO, et al. Impact of in-hospital bleeding according to the Bleeding Academic Research Consortium classification on the long-term adverse outcomes in patients undergoing percutaneous
coronary intervention. *Catheter Cardiovasc Interv* 2015; 85: 63–71.

25. Lincoff AM, Kleiman NS, Kereiakes DJ, et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. *JAMA* 2004; 292: 696–703.

26. Lopes RD, Alexander KP, Manoukian SV, et al. Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. *J Am Coll Cardiol* 2009; 53: 1021–1030.

27. Stone GW, Ware JH, Bertrand ME, et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. *JAMA* 2007; 298: 2497–2506.

28. Lemesle G, De Labriolle A, Bonello L, et al. Impact of bivalirudin on in-hospital bleeding and six-month outcomes in octogenarians undergoing percutaneous coronary intervention. *Catheter Cardiovasc Interv* 2009; 74: 428–435.

29. Venetsanos D, Lawesson SS, James S, et al. Bivalirudin versus heparin with primary percutaneous coronary intervention. *Am Heart J* 2018; 201: 9–16.